{
    "nctId": "NCT02044302",
    "briefTitle": "A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction",
    "officialTitle": "A Prospective Randomized Double Blind Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction",
    "overallStatus": "TERMINATED",
    "conditions": "Post-operative Pain",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Pain Score Questionnaire",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women undergoing immediate unilateral or bilateral tissue expander breast reconstruction following therapeutic skin-sparing or nipple-sparing mastectomy requiring postoperative expansions\n* Women undergoing immediate bilateral tissue expanders breast reconstruction following risk-reduction (prophylactic) skin-sparing or nipple-sparing mastectomy requiring postoperative tissue expansions.\n\nExclusion Criteria:\n\n* Subjects who are unable to read or speak English;\n* Breast reconstruction using the latissimus dorsi flap combined with a tissue expander;\n* Documented diagnosis of chronic pain, chronic migraine, upper limb spasticity, cervical dystonia, axillary hyperhidrosis, strabismus or blepharospasm;\n* Hypersensitivity to any botulinum toxin (BT) preparation or to any of the components in the formulation;\n* Infection at the proposed site of injection;\n* Pre-existing neuromuscular disorders (including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis);\n* Aminoglycosides intake at the time of surgery (these antibiotics can potentiate the effect of BT);\n* Women who are pregnant or breast feeding.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}